Background: Angiotensin converting enzyme 2 (ACE2) is a novel regulator of the renin-angiotensin system that counteracts the adverse effects of angiotensin II. ACE2 activity predicts adverse events and myocardial Ipilimumab supplier dysfunction in non-transplant patients with heart failure however there is limited data on the role of ACE2 in kidney transplant recipients. Methods: This is an ongoing prospective cohort study of patients with end-stage kidney disease undergoing kidney transplantation. Blood

collection is performed weekly for 12 weeks and then monthly for 12 months. Serum is transported on ice and aliquots frozen at −70°C. ACE2 enzyme activity was measured using an ACE2-specific quenched fluorescent substrate assay. The rate of substrate cleavage is expressed as pmol of substrate cleaved per mL of plasma per minute. Values below are expressed as mean ACE2 enzyme activity ± Standard https://www.selleckchem.com/products/azd-1208.html Deviation. Results: Analysis of pre-transplant ACE2 plasma activity (n = 12) demonstrated a baseline level of 18.4 ± 13.2 which increased significantly at week one (53.0 ± 27.9) (P < 0.05). ACE2 activity in

subsequent weeks gradually reduced towards the baseline level – Week 2 = 31.8 ± 11.5; Week 3 = 33.2 ± 21.1; Week 4 = 30.0 ± 15.2; Week 6 = 26.2 ± 15.7; and Week8 = 20.1 ± 8.5. Further analysis of

continuing samples are in progress. Conclusions: The present study demonstrates a significant surge in ACE2 during the critical early post-transplant period with physiological and immunological changes. The clinical implications of this early rise in ACE2 and compensatory regulatory role will be the focus of follow up studies. 258 THE PREFERENCES ID-8 AND PERSPECTIVES OF NEPHROLOGISTS ON PATIENTS’ ACCESS TO KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW A TONG1,2, CS HANSON1,2, JR CHAPMAN3, F HALLECK4, K BUDDE4, C PAPACHRISTOU4, JC CRAIG1,2 1The University of Sydney, Sydney, New South Wales; 2The Children’s Hospital at Westmead, Westmead, New South Wales; 3Westmead Hospital, Sydney, New South Wales, Australia; 4Charité – Universitätsmedizin Berlin, Germany Aim: To describe nephrologists’ attitudes to patients’ access to kidney transplantation. Background: While kidney transplantation can offer improved survival and quality of life outcomes, up to 70% of patients requiring renal replacement therapy remain on dialysis. Moreover disparities in access to kidney transplantation are apparent, in part attributable to differences in transplant education, screening, and patient eligibility for kidney transplantation. Methods: Electronic databases were searched to July 2013.